The handling of missing data in trial-based economic evaluations: should data be multiply imputed prior to longitudinal linear mixed-model analyses?

Author:

Ben Ângela JornadaORCID,van Dongen Johanna M.,Alili Mohamed El,Heymans Martijn W.,Twisk Jos W. R.,MacNeil-Vroomen Janet L.,de Wit Maartje,van Dijk Susan E. M.,Oosterhuis Teddy,Bosmans Judith E.

Abstract

Abstract Introduction For the analysis of clinical effects, multiple imputation (MI) of missing data were shown to be unnecessary when using longitudinal linear mixed-models (LLM). It remains unclear whether this also applies to trial-based economic evaluations. Therefore, this study aimed to assess whether MI is required prior to LLM when analyzing longitudinal cost and effect data. Methods Two-thousand complete datasets were simulated containing five time points. Incomplete datasets were generated with 10, 25, and 50% missing data in follow-up costs and effects, assuming a Missing At Random (MAR) mechanism. Six different strategies were compared using empirical bias (EB), root-mean-squared error (RMSE), and coverage rate (CR). These strategies were: LLM alone (LLM) and MI with LLM (MI-LLM), and, as reference strategies, mean imputation with LLM (M-LLM), seemingly unrelated regression alone (SUR-CCA), MI with SUR (MI-SUR), and mean imputation with SUR (M-SUR). Results For costs and effects, LLM, MI-LLM, and MI-SUR performed better than M-LLM, SUR-CCA, and M-SUR, with smaller EBs and RMSEs as well as CRs closers to nominal levels. However, even though LLM, MI-LLM and MI-SUR performed equally well for effects, MI-LLM and MI-SUR were found to perform better than LLM for costs at 10 and 25% missing data. At 50% missing data, all strategies resulted in relatively high EBs and RMSEs for costs. Conclusion LLM should be combined with MI when analyzing trial-based economic evaluation data. MI-SUR is more efficient and can also be used, but then an average intervention effect over time cannot be estimated.

Funder

Amsterdam Public Health Research Institute

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Reference55 articles.

1. WHO: 2015 Global Survey on Health Technology Assessment by National Authorities, https://www.who.int/health-technology-assessment/examples/en/, (2015)

2. Drummond, M.F., Sculpher, M.J., Torranc, G.W.: Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford (2005)

3. Petrou, S., Gray, A.: Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. The BMJ (2011). https://doi.org/10.1136/bmj.d1548

4. Rubin, D.B.: Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons (2004)

5. Faria, R., Gomes, M., Epstein, D., White, I.R.: A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics 32, 1157 (2014). https://doi.org/10.1007/s40273-014-0193-3

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3